Overview
Body Locations and Systems
Diagnosis and Therapy
Disorders and Conditions
ClinicalTrials.gov#
NCT04786262
Status
Recruiting
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Levina Ira, Research Assistant
Phone
Email Address
Purpose of Study
The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for type 1 diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar.
Volunteers will be given a thorough explanation of the trial and information about VX-880. Those who consent to participate will then undergo a comprehensive screening process. Following screening, all eligible participants will receive a one-time infusion at Vancouver General Hospital and remain on daily oral medications. Participation will involve a five-to-seven-day hospitalization for the infusion and monitoring, then follow-up visits and phone calls.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for type 1 diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar.
Volunteers will be given a thorough explanation of the trial and information about VX-880. Those who consent to participate will then undergo a comprehensive screening process. Following screening, all eligible participants will receive a one-time infusion at Vancouver General Hospital and remain on daily oral medications. Participation will involve a five-to-seven-day hospitalization for the infusion and monitoring, then follow-up visits and phone calls.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
